Dynavax Technologies ((DVAX)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dynavax Technologies is conducting a Phase 2 study titled ‘Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age.’ The study aims to evaluate the effectiveness, safety, and tolerability of the rF1V-1018 vaccine, which is significant for preventing pneumonic plague caused by aerosol exposure to Yersinia pestis.
The intervention being tested is a biological vaccine named rF1V-1018. This vaccine is designed to prevent pneumonic plague, a serious infectious disease.
The study employs a randomized, sequential intervention model with a quadruple masking approach. This means that participants, care providers, investigators, and outcomes assessors are blinded to the treatment being administered in some arms of the study. The primary purpose of the study is prevention.
The study began on October 2, 2025, and is currently recruiting participants. The primary completion and estimated study completion dates have not been disclosed. The last update was submitted on October 2, 2025, indicating that the study is actively progressing.
This study update could influence Dynavax Technologies’ stock performance positively if the vaccine shows promising results, as it would enhance the company’s portfolio in the vaccine market. Investor sentiment may also be affected by the involvement of the United States Department of Defense as a collaborator, highlighting the strategic importance of the vaccine.
The study is ongoing, and further details are available on the ClinicalTrials portal.